Overview
Translational oncology research firm's fiscal Q2 revenue rose 11% yr/yr to $15 mln
Company reported net income of $237,000 for fiscal Q2
Outlook
Company expects positive adjusted EBITDA for the full fiscal year
Champions Oncology anticipates year-over-year revenue growth
Result Drivers
BOOKINGS QUALITY - Improved bookings quality contributed to higher revenue conversion and growth
OPERATIONAL EFFICIENCIES - Oncology services margin improved to 52% due to operational efficiencies and stable costs
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$15 mln
$14.04 mln (1 Analyst)
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Champions Oncology Inc is $12.00, about 78.6% above its December 12 closing price of $6.72
Press Release: ID:nACSrwr9Xa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
